DME

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

Green Hills Software, STMicroelectronics and Cetitec Collaborate on Delivering Configurable In-Vehicle Communications Platform for Automotive Zonal Controllers

Retrieved on: 
Tuesday, April 9, 2024
Stellar, Cortex, OTA, Communication, Original equipment manufacturer, Memory, DME, LIN, Electronics, IDE, SDV, Abstract, ECU, Architecture, Écu, Heart, Safety, API, Ethernet, STMicroelectronics, R52

NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- Green Hills Software, the worldwide leader in embedded safety and security, together with STMicroelectronics, a global semiconductor leader serving customers across the spectrum of electronics applications, and Cetitec, a Porsche company and leading software specialist for the development of connectivity and networking system solutions, today announced a collaboration to deliver an integrated and configurable communications platform for use in zonal controllers for the centralized EE vehicle architecture of the SDV. This solution consists of Green Hills' µ-velOSity™ real-time operating system (RTOS), ST's Stellar Integration MCU platform, and Cetitec's advanced networking stacks, gateways and routing frameworks.

Key Points: 
  • This zonal-based centralized architecture has increased requirements for performance, safety and security of the zonal controllers and necessitates new in-vehicle networking solutions.
  • Based on this platform, Cetitec provides a demonstrator consisting of the Cetitec Gateway and the Cetitec Distributed Communications Framework (CDCF).
  • "Our collaboration with Cetitec and Green Hills on the Stellar platform brings safe and efficient solutions to our customers.
  • Green Hills, ST, and Cetitec will demonstrate the zonal controller solution platform at embedded world 2024, April 9-11, in the Green Hills booth #4-325 and in the ST booth #4A-148.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Noridian Continues To Support Providers and Suppliers Amid Change Healthcare Cyber Security Incident

Retrieved on: 
Thursday, March 14, 2024
American Samoa, DME, Change Healthcare, Senior, Medicare, CMS, Health insurance

FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.

Key Points: 
  • FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.
  • In collaboration with the Centers for Medicare & Medicaid Services (CMS), Noridian is offering multiple options for navigating billing challenges, including electronic workarounds.
  • Additionally, Noridian streamlines the process for requesting Accelerated and Advance Payments to provide financial relief to impacted providers.
  • Through collaborative efforts with the CMS and other stakeholders, Noridian is working to facilitate options to resolve the ongoing challenges posed by Change Healthcare’s cyber security incident.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

Retrieved on: 
Tuesday, March 12, 2024
Health, Hospitals, Neurology, Health Technology, Practice Management, Physical Therapy, HCPCS, Durable medical equipment, Brain, BCI, Patient, DME, Stroke, Classification, Survivor, Medicare, FDA, CMS, Movement, Rehabilitation, Medical device

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

Key Points: 
  • E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.
  • The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
  • CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME).
  • Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

DESERT MOUNTAIN ENERGY GENERAL OPERATIONAL UPDATE

Retrieved on: 
Monday, April 1, 2024
BTU, Nitrogen, BLM, DME, Light, Sale, Transport, CO2, Dehydration, Helium, Safety, Wildfire, Lithium

VANCOUVER, BC, April 1, 2024 /PRNewswire/ - DESERT MOUNTAIN ENERGY CORP. (the "Company") (TSXV: DME) (U.S. OTC: DMEHF) (Frankfurt: QM01) From the President of the Company.

Key Points: 
  • VANCOUVER, BC, April 1, 2024 /PRNewswire/ - DESERT MOUNTAIN ENERGY CORP. (the "Company") (TSXV: DME) (U.S. OTC: DMEHF) (Frankfurt: QM01) From the President of the Company.
  • The Company is pleased to update its shareholders on the current operational developments in New Mexico and Arizona.
  • These components were essential to meet end-user BTU requirements and upcoming industry changes in natural gas processing, safety, and transportation.
  • The dehydration, amine and high-pressure compression units are operational and currently processing gas.

Bonafide and Synthpop announce partnership at MedTrade 2024

Retrieved on: 
Tuesday, March 26, 2024
AI, Partnership, Durable medical equipment, Patient, DME, Software, Health, HME, Medical device

DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.

Key Points: 
  • DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.
  • The announcement comes during MedTrade 2024, the year's most anticipated Durable Medical Equipment (DME) conference.
  • Synthpop uses advanced AI solutions to streamline workflows, making it a perfect match to enhance and scale the Bonafide product offering.
  • The announcement of this partnership at MedTrade 2024 underscores both companies' commitment to advancing healthcare technology and improving patient outcomes.

DESERT MOUNTAIN ENERGY CORP. STATUS REPORT ON ANNUAL FINANCIAL STATEMENTS AND RELATED FILINGS

Retrieved on: 
Tuesday, March 12, 2024
Bank statement, DME, News, Requirement

VANCOUVER, BC, March 12, 2024 /PRNewswire/ - Desert Mountain Energy Corp. (the "Company" or "Desert Mountain") (TSXV: DME) was not able to file its annual audited financial statements for the year ended September 30, 2023 and its related MD&A, and other documents (the "Required Filings") as set out in its news release of January 30, 2024.

Key Points: 
  • VANCOUVER, BC, March 12, 2024 /PRNewswire/ - Desert Mountain Energy Corp. (the "Company" or "Desert Mountain") (TSXV: DME) was not able to file its annual audited financial statements for the year ended September 30, 2023 and its related MD&A, and other documents (the "Required Filings") as set out in its news release of January 30, 2024.
  • At this time, the Company is continuing to work on the Required Filings and has no further information on this matter.
  • The Company still anticipates that it will be in a position to remedy the default by filing the Required Filings no later than March 29, 2024.
  • The MCTO will be in effect until the Required Filings are filed.